Fujifilm Corp. said Wednesday it has signed an agreement with an Indian pharmaceutical company and a company that provides global medical supplies, granting them exclusive rights to develop, produce and sell its potential COVID-19 treatment drug Avigan overseas.
Under the tripartite agreement with India's Dr. Reddy's Laboratories Ltd. and Dubai-based Global Response Aid signed Tuesday, Fujifilm will receive a lump-sum license fee and royalties on sales of Avigan, also known as favipiravir, currently undergoing clinical testing as a possible coronavirus treatment drug in Japan.
Fujifilm Toyama Chemical Co., the Fujifilm subsidiary that developed Avigan, will provide the two companies with data accumulated so far on preclinical and clinical studies of the drug.